Wednesday, 22 May 2019

Overactive Bladder Treatment Market| Biopharma | Research & reports | DRG | MarketsandMarkets™


The overactive bladder treatment market includes various therapies, namely, anticholinergics, mirabegron, BOTOX, and neurostimulation used to treat the sudden, involuntary contraction of the muscle in the urinary bladder wall leading to urinary urgency, frequency, nocturia, and urge-incontinence. The global market is projected to be valued at USD 3.63 Billion in 2017 and is expected to grow at a CAGR of 2.9% during the forecast period to reach to USD 4.19 Billion by 2022. Base year considered for the report is 2016. The development of innovative intravesical therapies, aggressive marketing by pharma companies, and favorable demographics are the key factors driving the growth of the market.

To know about the assumptions considered for the study, download the pdf brochure


Objectives of the Study

  • ·         To define, describe, and forecast the global Overactive Bladder Treatment market on the basis of pharmacotherapy, disease type, and region
  • ·         To provide detailed information regarding the major factors influencing growth of the market (drivers, restraints, trends, opportunities, and challenges)
  • ·         To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the global market
  • ·         To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders


Browse and in-depth TOC on "Overactive Bladder Treatment Market"

53 - Tables
39 - Figures
236 - Pages

Get Free 10% customization:

Research Methodology

Top-down and bottom-up approaches were used to validate the size of the global Overactive Bladder Treatment market and estimate the size of other dependent submarkets. Various secondary sources such as associations, including American Urology Association, National Center for Biotechnology Information, U.S. National Library of Medicine, European Association of Urology, Urology Care Foundation, National Association For Continence, National Institutes of Health (NIH), Pharmaceutical Research and Manufacturers of America, Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), directories, industry journals, databases, and annual reports of the companies have been used to identify and collect information useful for the study of market.  

Target Audience:
  • ·         Drug manufacturers, vendors, and distributors
  • ·         Academic and government research institutes
  • ·         Contract manufacturing organizations (CMOs) and contract research organizations (CROs)
  • ·         Venture capitalists and investors


Overactive Bladder Treatment Market, by Disease Type

·         Idiopathic Bladder Overactivity
·         Neurogenic Bladder Overactivity

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

No comments:

Post a Comment